Trial Profile
Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen in Children Aged 12-23 Months at the Time of First Vaccination.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Pneumococcal vaccine (Primary) ; Pneumococcal 10-valent vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 31 Mar 2014 Results published in the Vaccine.
- 25 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 25 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.